Miyaki et al., 2016 - Google Patents
Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patientsMiyaki et al., 2016
- Document ID
- 7473574235757557523
- Author
- Miyaki E
- Imamura M
- Hiraga N
- Murakami E
- Kawaoka T
- Tsuge M
- Hiramatsu A
- Kawakami Y
- Aikata H
- Hayes C
- Chayama K
- Publication year
- Publication venue
- Hepatology Research
External Links
Snippet
Aim Although interferon (IFN)‐free antiviral therapy is expected to improve the treatment response for chronic hepatitis C, the effect on liver function and liver fibrosis is unknown. In this study, we analyzed the long‐term follow up of liver function parameters and liver fibrosis …
- 210000004185 Liver 0 title abstract description 66
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay for hepatitis non-A, non-B hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miyaki et al. | Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients | |
| Kobayashi et al. | Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection | |
| Watanabe et al. | Predictors of hepatocellular carcinoma occurrence after direct‐acting antiviral therapy in patients with hepatitis C virus infection | |
| Burstow et al. | Hepatitis C treatment: where are we now? | |
| Yoshimi et al. | Long term persistence of NS5A inhibitor‐resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy | |
| Chen et al. | Predictors of alpha‐fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a–ribavirin combination therapy | |
| Suda et al. | Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan | |
| Calle Serrano et al. | Development and evaluation of a baseline‐event‐anticipation score for hepatitis delta | |
| Degasperi et al. | Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives | |
| Niro et al. | HBsAg kinetics in chronic hepatitis D during interferon therapy: on‐treatment prediction of response | |
| Myers et al. | The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C | |
| HUANG et al. | Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1386‐patient study from Taiwan | |
| Inoue et al. | Changes in serum lipid profiles caused by three regimens of interferon‐free direct‐acting antivirals for patients infected with hepatitis C virus | |
| Yu | Hepatitis C treatment from “response‐guided” to “resource‐guided” therapy in the transition era from interferon‐containing to interferon‐free regimens | |
| Kosaka et al. | Emergence of resistant variants detected by ultra‐deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1 | |
| Kristiansen et al. | Total and cause‐specific mortality rates in a prospective study of community‐acquired hepatitis C virus infection in northern Norway | |
| Wu et al. | Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort | |
| Ogawa et al. | Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: a multicenter, real-world cohort study focusing on chronic kidney disease | |
| Morio et al. | Real‐world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus‐infected cirrhosis patients | |
| Mir et al. | African Americans are less likely to have clearance of hepatitis C virus infection: the findings from recent US population data | |
| Kurokawa et al. | Effect of interferon α‐2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis | |
| Hu et al. | Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of US veterans | |
| Huang et al. | The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients | |
| Kondo et al. | Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease | |
| Konishi et al. | Diabetes mellitus reduces the therapeutic effectiveness of interferon‐α2b plus ribavirin therapy in patients with chronic hepatitis C |